Joint Formulary & PAD

Oseltamivir phosphate - Influenza

You are here : Home > Formulary Search > Oseltamivir phosphate - Influenza

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Oral solution
  • Oral suspension
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
SPC
Restrictions / Comments :
Important

recommended for  treatment of influenza in adults and children meeting the criteria set out in NICE TA 168 and for prophylaxis of influenza in adults and children meeting the criteria set out in NICE TA 158

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Oseltamivir phosphate
Indication :
Influenza
Group Name :
Keywords :
prophylaxis
Brand Names Include :
Tamiflu
Important Information :
Latest Additions Date From :
01 Oct 2025
Latest Additions Date To :
31 Oct 2025
Guidelines :
Supporting Documents :
0

Committee Recommendations (2)

01 Oct 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The SLS has also been amended to remove current seasonal prescribing restrictions on oseltamivir (Tamiflu®) and zanamivir (Relenza®).

The change will enable primary care prescribers in England to prescribe influenza antivirals all year round, and not just within the period in which the Chief Medical and Pharmaceutical Officers have advised influenza is circulating in the community.

07 Aug 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

Other Indications

Below are listed other indications that Oseltamivir phosphate is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Influenza.